EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial

John M Kane, Roy Eshet, Eran Harary, Orna Tohami, Anna Elgart, Helena Knebel, Nir Sharon, Mark Suett, Kelli R Franzenburg, Glen L Davis, Christoph U Correll

CNS Drugs · 2024

DOI: 10.1007/s40263-024-01102-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CNS Drugs, 2024. Verfasst von John M Kane und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY, 11004, USA. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents, Risperidone. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Teva Branded Pharmaceutical Products R&D, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaAntipsychotic AgentsRisperidoneHumansDouble-Blind MethodMaleFemaleAdultInjections, SubcutaneousMiddle AgedDelayed-Action PreparationsYoung AdultTreatment Outcome

Substanzen

Antipsychotic AgentsRisperidoneDelayed-Action Preparations

Autor:innen und Institutionen

  • Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY, 11004, USA.
  • Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
  • Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, NY, USA.
  • Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
  • Global Patient Safety and Pharmacovigilance, Teva Pharmaceutical Industries Ltd. , Netanya, Israel.
  • Global Medical Affairs, Teva UK Limited, Harlow, UK.

Förderung

  • Teva Branded Pharmaceutical Products R&D, Inc.

Zitieren

APA

Kane, J. M., Eshet, R., Harary, E., Tohami, O., Elgart, A., Knebel, H., Sharon, N., Suett, M., Franzenburg, K. R., Davis, G. L., & Correll, C. U. (2024). A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. CNS Drugs. https://doi.org/10.1007/s40263-024-01102-2

Vancouver

Kane JM, Eshet R, Harary E, Tohami O, Elgart A, Knebel H, et al. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. CNS Drugs. 2024. doi:10.1007/s40263-024-01102-2

BibTeX
@article{Kane2024,
  author = {Kane, John M and Eshet, Roy and Harary, Eran and Tohami, Orna and Elgart, Anna and Knebel, Helena and Sharon, Nir and Suett, Mark and Franzenburg, Kelli R and Davis, Glen L and Correll, Christoph U},
  title = {A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial},
  journal = {CNS Drugs},
  year = {2024},
  doi = {10.1007/s40263-024-01102-2}
}
Kostenlos starten →